[{"id":"4a54cfbf-51b2-4dd6-a558-864138053bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04671303","created_at":"2021-01-19T20:44:39.986Z","updated_at":"2024-07-02T16:36:37.280Z","phase":"Phase 2","brief_title":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer","source_id_and_acronym":"NCT04671303","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • allitinib (AST1306)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2020-12-16"}]